JP4716731B2 - シャペロニン１０免疫抑制 - Google Patents

シャペロニン１０免疫抑制 Download PDF

Info

Publication number
JP4716731B2
JP4716731B2 JP2004548934A JP2004548934A JP4716731B2 JP 4716731 B2 JP4716731 B2 JP 4716731B2 JP 2004548934 A JP2004548934 A JP 2004548934A JP 2004548934 A JP2004548934 A JP 2004548934A JP 4716731 B2 JP4716731 B2 JP 4716731B2
Authority
JP
Japan
Prior art keywords
cpn10
cells
gvhd
transplantation
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004548934A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006508099A5 (enExample
JP2006508099A (ja
Inventor
ジェフリー アール． ヒル
タジャーナ バノビック
ヘイル モートン
アリス クリスティーナ カバナフ
Original Assignee
シーバイオ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シーバイオ リミテッド filed Critical シーバイオ リミテッド
Publication of JP2006508099A publication Critical patent/JP2006508099A/ja
Publication of JP2006508099A5 publication Critical patent/JP2006508099A5/ja
Application granted granted Critical
Publication of JP4716731B2 publication Critical patent/JP4716731B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Glass Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2004548934A 2002-11-06 2003-11-06 シャペロニン１０免疫抑制 Expired - Fee Related JP4716731B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2002952492 2002-11-06
AU2002952492A AU2002952492A0 (en) 2002-11-06 2002-11-06 Chaperonin 10 immunosuppression
PCT/AU2003/001467 WO2004041300A1 (en) 2002-11-06 2003-11-06 Chaperonin 10 immunosuppression

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010286005A Division JP2011088920A (ja) 2002-11-06 2010-12-22 シャペロニン１０免疫抑制

Publications (3)

Publication Number Publication Date
JP2006508099A JP2006508099A (ja) 2006-03-09
JP2006508099A5 JP2006508099A5 (enExample) 2007-04-12
JP4716731B2 true JP4716731B2 (ja) 2011-07-06

Family

ID=28795882

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004548934A Expired - Fee Related JP4716731B2 (ja) 2002-11-06 2003-11-06 シャペロニン１０免疫抑制
JP2010286005A Pending JP2011088920A (ja) 2002-11-06 2010-12-22 シャペロニン１０免疫抑制

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010286005A Pending JP2011088920A (ja) 2002-11-06 2010-12-22 シャペロニン１０免疫抑制

Country Status (16)

Country Link
US (3) US7618935B2 (enExample)
EP (3) EP2255824B1 (enExample)
JP (2) JP4716731B2 (enExample)
KR (1) KR101088740B1 (enExample)
CN (1) CN100525832C (enExample)
AT (1) ATE489963T1 (enExample)
AU (1) AU2002952492A0 (enExample)
CA (1) CA2505141C (enExample)
CY (1) CY1110972T1 (enExample)
DE (1) DE60335202D1 (enExample)
DK (1) DK1569679T3 (enExample)
ES (1) ES2351993T3 (enExample)
NZ (1) NZ540433A (enExample)
PT (1) PT1569679E (enExample)
SI (1) SI1569679T1 (enExample)
WO (1) WO2004041300A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007517808A (ja) 2004-01-16 2007-07-05 キュビオ リミテッド Ｔｏｌｌ様受容体誘導性のサイトカインおよびケモカイン分泌のシャペロニン１０調節
AU2005204979B2 (en) * 2004-01-16 2010-10-21 Cbio Limited Chaperonin 10 modulation of toll-like receptor-inducible cytokine and chemokine secretion
US8036710B2 (en) * 2004-05-07 2011-10-11 Qualcomm, Incorporated Power-efficient multi-antenna wireless device
AU2006269824B2 (en) * 2005-07-11 2012-04-19 Cbio Limited Chaperonin 10-induced immunomodulation
EP1906989A4 (en) 2005-07-11 2009-08-19 Cbio Ltd IMMUNOMODULATION INDUCED BY CHAPERONIN 10
EP2463307A1 (en) 2005-08-31 2012-06-13 CBIO Limited Modified chaperonin 10
AU2006303826B2 (en) * 2005-10-20 2012-07-19 Cbio Limited Treatment of hypersensitivity
CA2626692A1 (en) * 2005-10-20 2007-04-26 Cbio Limited Treatment of hypersensitivity
MX2008011167A (es) 2006-03-02 2008-11-12 Cbio Ltd Regulaciòn de respuestas inmunes mediante la modulaciòn de la funciòn de cèlulas presentadoras de antìgenos.
CA2720617A1 (en) * 2008-04-11 2009-10-15 Cbio Limited Modified cpn10 and prr signalling
US20110243921A1 (en) * 2010-03-30 2011-10-06 Cbio Limited Prevention and treatment of cutaneous lupus erythematosus
WO2013158959A1 (en) * 2012-04-19 2013-10-24 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of graft-versus-host disease
WO2014063194A1 (en) 2012-10-23 2014-05-01 The University Of Sydney Elastic hydrogel
US10842913B2 (en) 2012-12-10 2020-11-24 Allergan Pharmaceuticals International Limited Scalable three-dimensional elastic construct manufacturing
RU2677637C2 (ru) 2013-08-13 2019-01-18 Эластаджен Пти Лтд Регенерация поврежденной ткани

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2176948C (en) * 1993-11-30 2007-05-15 Halle Morton Chaperonin 10
WO1995015338A1 (en) 1993-11-30 1995-06-08 The University Of Queensland Chaperonin 10
US5989804A (en) * 1994-07-08 1999-11-23 New England Medical Center Hospitals, Inc. E6 binding proteins
EP0845994A1 (en) * 1995-08-09 1998-06-10 Schering Corporation Combined use of interleukin-10 and cyclosporin for immunosuppression therapy
US20020142000A1 (en) * 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
EP1218030A4 (en) 1999-09-10 2004-09-15 Univ Fordham METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING TRANSPLANT REJECTION BY USING HEAT SHOCK PROTEINS
GB0028122D0 (en) * 2000-11-17 2001-01-03 St Georges Entpr Ltd Method

Also Published As

Publication number Publication date
CN1735428A (zh) 2006-02-15
US20120082690A1 (en) 2012-04-05
EP1569679A4 (en) 2008-02-27
EP2255824B1 (en) 2014-07-23
EP1569679B1 (en) 2010-12-01
DK1569679T3 (da) 2011-01-10
AU2002952492A0 (en) 2002-11-21
EP2255824A1 (en) 2010-12-01
ES2351993T3 (es) 2011-02-14
US7618935B2 (en) 2009-11-17
SI1569679T1 (sl) 2011-01-31
KR101088740B1 (ko) 2011-12-01
CA2505141A1 (en) 2004-05-21
WO2004041300A1 (en) 2004-05-21
PT1569679E (pt) 2010-12-14
ATE489963T1 (de) 2010-12-15
EP2818179A1 (en) 2014-12-31
CY1110972T1 (el) 2015-06-11
US8067361B2 (en) 2011-11-29
US20060198834A1 (en) 2006-09-07
NZ540433A (en) 2008-03-28
KR20050086428A (ko) 2005-08-30
DE60335202D1 (en) 2011-01-13
US20100099605A1 (en) 2010-04-22
CN100525832C (zh) 2009-08-12
CA2505141C (en) 2012-07-17
JP2006508099A (ja) 2006-03-09
EP1569679A1 (en) 2005-09-07
JP2011088920A (ja) 2011-05-06

Similar Documents

Publication Publication Date Title
US8067361B2 (en) Chaperonin 10 immunosuppression
Williams Collagen-induced arthritis as a model for rheumatoid arthritis
US10086046B2 (en) Agent for the treatment and or prophylaxis of an autoimmune disease and for the formation of regulatory T cells
JP3798426B2 (ja) 自己免疫疾患の治療におけるｉｌ−１２およびｉｌ−１２アンタゴニストの使用
US6007821A (en) Method and compositions for the treatment of autoimmune disease using heat shock proteins
JPH09509944A (ja) Ｔ細胞調節のための製品と方法
IL194987A (en) Use of PIF peptide to produce a drug to regulate the immune system
Choi et al. Transplantation of CTLA4Ig gene‐transduced adipose tissue‐derived mesenchymal stem cells reduces inflammatory immune response and improves Th1/Th2 balance in experimental autoimmune thyroiditis
PL186568B1 (pl) Homogenne i rekombinowane, biologicznie czynne białka otyłości oraz ich fragmenty, białko fuzyjne, wektor ekspresyjny, sekwencje DNA, organizm gospodarza E. coli, sposób wytwarzania biologicznie czynnego, rekombinowanego ludzkiego białka otyłości i kompozycje farmaceutyczne
Heeringa et al. Pathophysiology of ANCA-associated vasculitides: are ANCA really pathogenic?
JP2000516570A (ja) アレルギー反応の標的治療のためのＦｃε―ＰＥキメラタンパク質、その製造方法、及びそれを含む薬剤組成物
US20120082644A1 (en) Cytokines and neuroantigens for treatment of immune disorders
WO1992006117A1 (en) Inhibiting unwanted immune responses
Ramiya et al. Effect of oral and intravenous insulin and glutamic acid decarboxylase in NOD mice
AU2005223469A1 (en) Immunosuppressive cytokine
AU2003277992B2 (en) Chaperonin 10 immunosuppression
Novoselova et al. Production of heat shock proteins, cytokines, and nitric oxide in toxic stress
Smith et al. Mediators of asthma
JP2013512279A (ja) ＩｇＥ媒介性疾患の処置方法
US20040116344A1 (en) Immunomodulatory properties of bip
WO2001089555A1 (en) Compositions with anti-proliferative activities and methods for use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061101

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20091120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100422

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100823

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101118

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101126

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110302

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110329

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140408

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees